STOCK TITAN

Pacific Biosciences of California Inc - PACB STOCK NEWS

Welcome to our dedicated news page for Pacific Biosciences of California (Ticker: PACB), a resource for investors and traders seeking the latest updates and insights on Pacific Biosciences of California.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pacific Biosciences of California's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pacific Biosciences of California's position in the market.

Rhea-AI Summary
PacBio (PACB) partners with the University of Tartu to sequence 10,000 human genomes using the Revio HiFi system, supported by EU and Estonian government funding. This collaboration aims to advance personalized medicine and healthcare innovation in Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.68%
Tags
none
-
Rhea-AI Summary
PacBio (PACB) granted a non-qualified stock option and restricted stock units to a new employee under an inducement plan. The options have an exercise price of $3.67 per share and vest over time, while the RSUs vest on specific anniversaries. The awards are subject to the 2020 Inducement Plan and employee agreements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
none
-
Rhea-AI Summary
PacBio introduces the PureTarget repeat expansion panel for comprehensive analysis of 20 genes linked to neurological diseases. The new long-read sequencing workflow aims to identify disease-causing variants and methylation signatures efficiently, offering a commercial opportunity in large laboratories.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.86%
Tags
clinical trial
Rhea-AI Summary
PacBio (PACB) to participate in upcoming investor conferences, including TD Cowen 44th Annual Health Care Conference and Barclays 26th Annual Global Healthcare Conference. Live webcasts and replays will be accessible on the company's investor page.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.46%
Tags
conferences
-
Rhea-AI Summary
PacBio (PACB) reports fourth-quarter revenue of $58.4 million, a 113% increase year-over-year, with strong growth in instrument revenue. However, the company faces a net loss of $82.0 million for the quarter. Fiscal year 2023 revenue reaches $200.5 million, showing a 56% increase, but the net loss is $306.7 million. PacBio introduces new products and software updates to enhance its sequencing capabilities and collaborates with research institutions for genetic disease studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.94%
Tags
earnings
-
Rhea-AI Summary
VOLO Events Agency Wins Best Event Technology Award at BizBash Awards for PacBio Product Launch, Featuring Immersive Technology and Maroon 5 Performance
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.39%
Tags
none
Rhea-AI Summary
PacBio (PACB) announced two new high throughput library preparation kits and workflows optimized for its Revio sequencing system, offering automated, scalable, and high-performance solutions with a 40% reduction in costs and a 60% decrease in workflow time. The HiFi Plex Prep Kit 96 now includes 384 validated barcode adapters, allowing customers to run 1,536 samples in a single Revio run. These new kits aim to bring scale, savings, and speed never before possible on Revio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.59%
Tags
none
-
Rhea-AI Summary
PacBio (PACB) will hold a conference call to discuss its Q4 2023 financial results on February 15, 2024, at 5:00 pm ET. The call will be webcast and can be accessed on PacBio's website. Dial-in options are also available for live listening or replay.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
conferences earnings
-
Rhea-AI Summary
PacBio (PACB) announces the launch of PanDNA, a Nanobind DNA extraction kit designed to enable high-throughput extraction of high molecular weight DNA for HiFi sequencing. The PanDNA kit expands the range of sample types suitable for long-read sequencing, including cells, bacteria, blood, tissue, plant nuclei, and insects. The existing Nanobind HT CBB kit has been updated to support two new sample types – animal blood and bacteria – and can accommodate 96 samples per run. The new PanDNA kit is expected to be available in February 2024, while the Nanobind HT CBB kit is available now.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
TurnCare, a leading medical technology and services company dedicated to advancing how hospitals manage high acuity patients, proudly announces the addition of John F. Milligan, Ph.D., investor, innovator, and former CEO of Gilead, to its Board of Directors. Dr. Milligan's expertise includes driving major acquisitions to create unique industry solutions and scaling Gilead to over $21 Billion in worldwide sales with a market cap of $85 Billion. He brings a unique and valuable perspective that will help TurnCare maximize the impact of its novel patient management technologies as it scales to more networks, hospitals, and patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
management
Pacific Biosciences of California Inc

Nasdaq:PACB

PACB Rankings

PACB Stock Data

996.78M
266.44M
2.8%
101.76%
16.25%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States
Menlo Park

About PACB

pacbio develops comprehensive solutions for scientists that propel the field of genomics, improve science and research, and create positive impact globally. we provide sophisticated genomic analysis systems that deliver invaluable insights for scientists who strive to resolve complex genetic challenges. our strength comes from the dedication of our people, who are fueled by a desire to effect real, positive change. with a focus on the future and an experienced, passionate team, we are motivated to continue to redefine what is possible in genomics.